NAV
$121.04
AUM
$341.2M
Expense Ratio
-
Dividend Yield
0.85%
Beta
0.50
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +15.66% | +9.13% | +17.67% | +50.22% | +18.32% | +9.33% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 5.38% |
| 2 | CORT | Corcept Therapeutics Inc | 5.34% |
| 3 | LQDA | Liquidia Corp Ordinary Shares | 5.17% |
| 4 | PFE | Pfizer Inc | 4.89% |
| 5 | MRK | Merck & Co Inc | 4.85% |
| 6 | ABBV | AbbVie Inc | 4.83% |
| 7 | JNJ | Johnson & Johnson | 4.64% |
| 8 | GILD | Gilead Sciences Inc | 4.61% |
| 9 | AMGN | Amgen Inc | 4.45% |
| 10 | TVTX | Travere Therapeutics Inc Ordinary Shares | 4.29% |
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Inception Date: 2005-06-23